New drug targets 'Undruggable' cancer mutation in early human trial
NCT ID NCT04449874
Summary
This is an early-stage study to find a safe dose and see how the body processes a new drug called GDC-6036. It is being tested alone and with other cancer drugs in people with advanced solid tumors, like lung or colorectal cancer, that have a specific genetic change called KRAS G12C. The main goals are to check for side effects and see if the drug shows any early signs of helping to control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ St Maarten Campus Leopoldstr
Mechelen, 2800, Belgium
-
Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
Alfred Health
Melbourne, Victoria, 3004, Australia
-
Asan Medical Center - PPDS
Seoul, 05505, South Korea
-
Asst Grande Ospedale Metropolitano Niguarda
Milan, Lombardy, 20162, Italy
-
Auckland City Hospital
Auckland, New Zealand
-
Auckland City Hospital, Cancer and Blood Research
Auckland, 1023, New Zealand
-
Azienda Ospedaliero Universitaria Pisana
Pisa, Tuscany, 56100, Italy
-
Biokinetica, Przychodnia Jozefow
Józefów, 05-410, Poland
-
CHU de Liège
Liège, 4000, Belgium
-
Chao Family Comprehensive Cancer Center UCI
Orange, California, 92868, United States
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Clinexpert Gyongyos Kft
Gyöngyös, 3200, Hungary
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Haukeland University Hospital
Bergen, 5020, Norway
-
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam, 1066 CX, Netherlands
-
Hospital Clinico Universitario Virgen de la Victoria
Málaga, 29010, Spain
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Erasto Gaertner
Curitiba, Paraná, 81520-060, Brazil
-
Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)
Porto Alegre, Rio Grande do Sul, 90610-000, Brazil
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario HM Sanchinarro-CIOCC
Madrid, 28050, Spain
-
Hospital Universitario Virgen del Rocío
Seville, 41013, Spain
-
Hospital de Clinicas de Porto Alegre HCPA PPDS
Pôrto Alegre, Pará, 90035-903, Brazil
-
Hôpitaux Universitaires de Genève
Geneva, 1211, Switzerland
-
Inselspital
Bern, 3010, Switzerland
-
Instituto Nacional de Câncer
Rio de Janeiro, 20230-130, Brazil
-
Irccs Ospedale San Raffaele
Milan, Lombardy, 20132, Italy
-
Istituto Clinico Humanitas
Rozzano (MI), Lombardy, 20089, Italy
-
Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS
Meldola, Emilia-Romagna, 47014, Italy
-
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
-
Leids Universitair Medisch Centrum
Leiden, 2333 ZA, Netherlands
-
Linear Clinical Research Limited
Nedlands, Western Australia, 6009, Australia
-
Maastricht University Medical Center
Maastricht, 6229 HX, Netherlands
-
New Zealand Clinical Research - Christchurch
Christchurch, New Zealand
-
Oslo university hospital Radiumhospitalet
Oslo, 0424, Norway
-
Ottawa Hospital
Ottawa, Ontario, K1H 8L6, Canada
-
Peter MacCallum Cancer Center
Melbourne, Victoria, 3000, Australia
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Queen Elizabeth Hospital
Birmingham, B15 2GW, United Kingdom
-
Rambam Medical Center
Haifa, 3109601, Israel
-
START Madrid-FJD, Hospital Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Samsung Medical Center - PPDS
Seoul, 06351, South Korea
-
Santa Casa de Misericordia de Belo Horizonte - PPDS
Belo Horizonte, Minas Gerais, 30150-221, Brazil
-
Seoul National University Bundang Hospital
Seongnam-si, 13605, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Sheba Medical Center - PPDS
Ramat Gan, 52621, Israel
-
Slade Health Inward goods
Mount Kuring-Gai, New South Wales, 2080, Australia
-
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, 2010, Australia
-
Tel-Aviv Sourasky Medical Center
Tel Aviv, 6423906, Israel
-
The Aga Khan University-Kenya.
Nairobi, 00100, Kenya
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
UCSD Moores Cancer Center
La Jolla, California, 92093, United States
-
UPMC - Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
UZ Antwerpen
Edegem, 2650, Belgium
-
Universidade de Caxias do Sul
Caxias do Sul, Rio Grande do Sul, 95070-561, Brazil
-
Universitair Medisch Centrum Utrecht
Utrecht, 3584 CX, Netherlands
-
University College London Hospitals NHS Foundation Trust
London, W1T 7HA, United Kingdom
-
University of Oklahoma
Oklahoma City, Oklahoma, 73104, United States
-
Uniwersyteckie Centrum Kliniczne, O?rodek Bada? Klinicznych Wczesnych Faz
Gdansk, 80-214, Poland
-
Velindre Cancer Centre
Cardiff, CF14 2TL, United Kingdom
-
Yale Cancer Center
New Haven, Connecticut, 06511, United States
Conditions
Explore the condition pages connected to this study.